New Cholesterol Guidelines Expand Statin Eligibility to Younger, Lower-Risk Adults

American medicine has quietly shifted the boundary between the healthy and the at-risk, with new 2026 guidelines extending statin therapy to more than half of all U.S. adults—including younger people and those once considered low-risk. The move reflects a deepening faith in pharmaceutical prevention, but also surfaces enduring tensions around equity, cost, and the meaning of treating risk rather than disease. As the circle of eligibility widens, so too does the question of who benefits, who bears the burden, and whose vulnerability the system is truly designed to see.